Compare Vanguard S&P 500 Growth Index Fund ETF (VOOG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 Growth Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard S&P 500 Growth Index Fund ETF trades at $81.91, while State Street SPDR S&P Biotech ETF trades at $154.32. Which is the better fit depends on your goals.
| VOOG | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $85.11 | $164.28 |
52-Week Low | $65.32 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOOG (Vanguard S&P 500 Growth ETF) trades at $80.98, up 0.28% with a bearish technical signal from moving averages. The ETF provides exposure to 212 large-cap growth stocks with a 0.07% expense ratio and heavy technology sector concentration. Recent news highlights comparisons with other growth ETFs, noting VOOG's strong long-term performance and competitive fee structure.
The outlook remains cautious due to bearish technical indicators and concentrated tech exposure, though the low expense ratio and S&P 500 growth focus provide structural advantages. Key risks include tech sector volatility and market sentiment shifts, while institutional interest remains steady given Vanguard's reputation and the ETF's track record.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
